Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated
to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related …

Background The novel proteasome inhibitor carfilzomib alone or in combination with other
agents is already one of the standard therapies for relapsed and/or refractory multiple …

Abstract Purpose of Review Multiple myeloma is a common hematologic malignancy
characterized by recurrent relapsing disease course requiring use of various therapies. Over …

Importance Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple
myeloma can be potentially life-threatening and remain incompletely characterized. We …

Purpose of review Multiple myeloma treatment regimens consist of proteasome inhibitors
(bortezomib, carfilzomib, and ixazomib), immunomodulatory drugs (thalidomide …

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological
cancers. It predominantly affects elderly people; median age at diagnosis is 70 years …

With the continuous improvement in survival of cancer patients, including those with multiple
myeloma, related to the novel treatment agents and therapeutic approaches, the probability …

Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then
there have been concerns for cardiovascular toxicity from its use. With this study, we aim to …

Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or
refractory multiple myeloma (RRMM). It has significantly improved outcomes, including …

Importance Multiple myeloma (MM) is the second most common hematological malignant
abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors …